+

WO2001096584A3 - Materials and methods for the control of nematodes - Google Patents

Materials and methods for the control of nematodes Download PDF

Info

Publication number
WO2001096584A3
WO2001096584A3 PCT/US2001/018911 US0118911W WO0196584A3 WO 2001096584 A3 WO2001096584 A3 WO 2001096584A3 US 0118911 W US0118911 W US 0118911W WO 0196584 A3 WO0196584 A3 WO 0196584A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
nematodes
control
materials
subject invention
Prior art date
Application number
PCT/US2001/018911
Other languages
French (fr)
Other versions
WO2001096584A2 (en
Inventor
Arcady R Mushegian
Christopher G Taylor
Jerald S Feitelson
Alexy M Eroshkin
Original Assignee
Akkadix Corp
Arcady R Mushegian
Christopher G Taylor
Jerald S Feitelson
Alexy M Eroshkin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akkadix Corp, Arcady R Mushegian, Christopher G Taylor, Jerald S Feitelson, Alexy M Eroshkin filed Critical Akkadix Corp
Priority to AU2001275474A priority Critical patent/AU2001275474A1/en
Publication of WO2001096584A2 publication Critical patent/WO2001096584A2/en
Publication of WO2001096584A3 publication Critical patent/WO2001096584A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8261—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield
    • C12N15/8271—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance
    • C12N15/8279—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance
    • C12N15/8285—Phenotypically and genetically modified plants via recombinant DNA technology with agronomic (input) traits, e.g. crop yield for stress resistance, e.g. heavy metal resistance for biotic stress resistance, pathogen resistance, disease resistance for nematode resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
    • C07K14/4354—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from nematodes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/10—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in agriculture
    • Y02A40/146—Genetically Modified [GMO] plants, e.g. transgenic plants

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

The subject invention provides novel methods and compositions for controlling nematodes. More specifically, the subject invention provides RNAi molecules, polynucleotide sequences, and methods of using these sequences in nematode control.
PCT/US2001/018911 2000-06-12 2001-06-12 Materials and methods for the control of nematodes WO2001096584A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2001275474A AU2001275474A1 (en) 2000-06-12 2001-06-12 Materials and methods for the control of nematodes

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21091700P 2000-06-12 2000-06-12
US60/210,917 2000-06-12

Publications (2)

Publication Number Publication Date
WO2001096584A2 WO2001096584A2 (en) 2001-12-20
WO2001096584A3 true WO2001096584A3 (en) 2003-01-23

Family

ID=22784842

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/018911 WO2001096584A2 (en) 2000-06-12 2001-06-12 Materials and methods for the control of nematodes

Country Status (2)

Country Link
AU (1) AU2001275474A1 (en)
WO (1) WO2001096584A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7176304B2 (en) 2002-02-20 2007-02-13 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides

Families Citing this family (392)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211711B2 (en) * 1999-03-25 2007-05-01 Arborgen, Llc Compositions and methods for the modification of gene expression
US7491805B2 (en) 2001-05-18 2009-02-17 Sirna Therapeutics, Inc. Conjugates and compositions for cellular delivery
US7833992B2 (en) 2001-05-18 2010-11-16 Merck Sharpe & Dohme Conjugates and compositions for cellular delivery
WO2003070918A2 (en) * 2002-02-20 2003-08-28 Ribozyme Pharmaceuticals, Incorporated Rna interference by modified short interfering nucleic acid
US20080032942A1 (en) 2000-08-30 2008-02-07 Mcswiggen James RNA interference mediated treatment of Alzheimer's disease using short interfering nucleic acid (siNA)
EP1386004A4 (en) 2001-04-05 2005-02-16 Ribozyme Pharm Inc Modulation of gene expression associated with inflammation proliferation and neurite outgrowth, using nucleic acid based technologies
US20050014172A1 (en) 2002-02-20 2005-01-20 Ivan Richards RNA interference mediated inhibition of muscarinic cholinergic receptor gene expression using short interfering nucleic acid (siNA)
US20050159378A1 (en) 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20050256068A1 (en) 2001-05-18 2005-11-17 Sirna Therapeutics, Inc. RNA interference mediated inhibition of stearoyl-CoA desaturase (SCD) gene expression using short interfering nucleic acid (siNA)
US9994853B2 (en) 2001-05-18 2018-06-12 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US8008472B2 (en) 2001-05-29 2011-08-30 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of human immunodeficiency virus (HIV) gene expression using short interfering nucleic acid (siNA)
US7294504B1 (en) 2001-12-27 2007-11-13 Allele Biotechnology & Pharmaceuticals, Inc. Methods and compositions for DNA mediated gene silencing
JP4527984B2 (en) † 2002-02-01 2010-08-18 ライフ テクノロジーズ コーポレーション Oligonucleotide composition having enhanced efficacy
EP1572902B1 (en) * 2002-02-01 2014-06-11 Life Technologies Corporation HIGH POTENCY siRNAS FOR REDUCING THE EXPRESSION OF TARGET GENES
US7795422B2 (en) 2002-02-20 2010-09-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of hypoxia inducible factor 1 (HIF1) gene expression using short interfering nucleic acid (siNA)
US7897752B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of telomerase gene expression using short interfering nucleic acid (siNA)
US7897757B2 (en) 2002-02-20 2011-03-01 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of protein tyrosine phosphatase-1B (PTP-1B) gene expression using short interfering nucleic acid (siNA)
US7935812B2 (en) 2002-02-20 2011-05-03 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of hepatitis C virus (HCV) expression using short interfering nucleic acid (siNA)
US20090099117A1 (en) 2002-02-20 2009-04-16 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF MYOSTATIN GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7678897B2 (en) 2002-02-20 2010-03-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of platelet-derived endothelial cell growth factor (ECGF1) gene expression using short interfering nucleic acid (siNA)
US7683165B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US9181551B2 (en) 2002-02-20 2015-11-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7910724B2 (en) 2002-02-20 2011-03-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Fos gene expression using short interfering nucleic acid (siNA)
US7683166B2 (en) 2002-02-20 2010-03-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of interleukin and interleukin receptor gene expression using short interfering nucleic acid (siNA)
US8013143B2 (en) 2002-02-20 2011-09-06 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of CXCR4 gene expression using short interfering nucleic acid (siNA)
US7667029B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of checkpoint kinase-1 (CHK-1) gene expression using short interfering nucleic acid (siNA)
US7662952B2 (en) 2002-02-20 2010-02-16 Sirna Therapeutics, Inc. RNA interference mediated inhibition of GRB2 associated binding protein (GAB2) gene expression using short interfering nucleic acid (siNA)
US20090253774A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF PLATELET DERIVED GROWTH FACTOR (PDGF) AND PLATELET DERIVED GROWTH FACTOR RECEPTOR (PDGFR) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US7928220B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of stromal cell-derived factor-1 (SDF-1) gene expression using short interfering nucleic acid (siNA)
US20090192105A1 (en) 2002-02-20 2009-07-30 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF INTERCELLULAR ADHESION MOLECULE (ICAM) GENE EXPRESSION USING SHORT INTERFERING NUCELIC ACID (siNA)
US7893248B2 (en) 2002-02-20 2011-02-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US8067575B2 (en) 2002-02-20 2011-11-29 Merck, Sharp & Dohme Corp. RNA interference mediated inhibition of cyclin D1 gene expression using short interfering nucleic acid (siNA)
US7897753B2 (en) 2002-02-20 2011-03-01 Sirna Therapeutics, Inc. RNA interference mediated inhibition of XIAP gene expression using short interfering nucleic acid (siNA)
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US7928219B2 (en) 2002-02-20 2011-04-19 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of placental growth factor gene expression using short interfering nucleic acid (SINA)
US7691999B2 (en) 2002-02-20 2010-04-06 Sirna Therapeutics, Inc. RNA interference mediated inhibition of NOGO and NOGO receptor gene expression using short interfering nucleic acid (siNA)
US20090253773A1 (en) 2002-02-20 2009-10-08 Sirna Therapeutics, Inc. RNA INTERFERENCE MEDIATED INHIBITION OF TNF AND TNF RECEPTOR GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
CA2457528C (en) 2002-02-20 2011-07-12 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis c virus (hcv) gene expression using short interfering nucleic acid (sina)
US8258288B2 (en) 2002-02-20 2012-09-04 Sirna Therapeutics, Inc. RNA interference mediated inhibition of respiratory syncytial virus (RSV) expression using short interfering nucleic acid (siNA)
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US7667030B2 (en) 2002-02-20 2010-02-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of matrix metalloproteinase 13 (MMP13) gene expression using short interfering nucleic acid (siNA)
US7700760B2 (en) 2002-02-20 2010-04-20 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular cell adhesion molecule (VCAM) gene expression using short interfering nucleic acid (siNA)
SI1504126T1 (en) 2002-05-03 2014-08-29 Duke University Office Of Science And Technology A method of regulating gene expression
US7803984B2 (en) * 2002-07-10 2010-09-28 Kansas State University Research Foundation Compositions and methods for controlling plant parasitic nematodes
US20080260744A1 (en) 2002-09-09 2008-10-23 Omeros Corporation G protein coupled receptors and uses thereof
US8158420B2 (en) 2003-04-04 2012-04-17 The Trustees Of Columbia University In The City Of New York Methods for inhibiting the differentation of proliferative telencephalic cells in vitro by addition of ATF5
WO2005000403A2 (en) 2003-05-19 2005-01-06 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof
EP1716238B1 (en) * 2003-12-23 2017-12-06 Bayer S.A.S. Method for modifying gene expression of a phytopathogenic fungus
CA2554212A1 (en) 2004-02-10 2005-08-25 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using multifunctional short interfering nucleic acid (multifunctional sina)
US7622301B2 (en) * 2004-02-24 2009-11-24 Basf Plant Science Gmbh Compositions and methods using RNA interference for control of nematodes
US10508277B2 (en) 2004-05-24 2019-12-17 Sirna Therapeutics, Inc. Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference
US7868158B2 (en) 2004-07-19 2011-01-11 Baylor College Of Medicine Modulation of cytokine signaling regulators and applications for immunotherapy
AR050211A1 (en) 2004-08-13 2006-10-04 Basf Plant Science Gmbh COMPOSITIONS AND METHODS THAT USE RNA INTERFERENCE FOR NEMATODE CONTROL
US20060247197A1 (en) 2004-10-04 2006-11-02 Van De Craen Marc Method for down-regulating gene expression in fungi
WO2006044480A2 (en) 2004-10-13 2006-04-27 University Of Georgia Research Foundation, Inc. Nematode resistant transgenic plants
ES2444001T3 (en) 2004-10-21 2014-02-21 Venganza Inc. Procedures and materials to confer resistance to plant pests and pathogens
US9944713B2 (en) 2004-11-24 2018-04-17 Medicinal Bioconvergence Research Center Antibody specific to the AIMP2-DX2
EP2500429A3 (en) 2005-05-31 2015-10-28 Devgen N.V. RNAi for the control of insects and arachnids
US7868159B2 (en) 2005-06-23 2011-01-11 Baylor College Of Medicine Modulation of negative immune regulators and applications for immunotherapy
EP1965814A4 (en) 2005-09-26 2012-01-11 Univ Columbia CELLS OF LATERAL POPULATION INVOLVED IN HEART REPAIR
US20090285784A1 (en) * 2006-01-12 2009-11-19 Devgen Nv DSRNA As Insect Control Agent
EP1971687A2 (en) * 2006-01-12 2008-09-24 Devgen NV Dsrna as insect control agent
WO2007104570A2 (en) * 2006-03-16 2007-09-20 Devgen N.V. Nematode control
US8524454B2 (en) 2006-04-07 2013-09-03 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
US9044461B2 (en) 2006-04-07 2015-06-02 The Research Foundation Of State University Of New York Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency
CN101605896A (en) 2007-02-06 2009-12-16 巴斯福植物科学有限公司 Use the composition and the method for RNA interference for control of nematodes
CN101605894A (en) 2007-02-08 2009-12-16 巴斯福植物科学有限公司 Composition and method with the RNA interference for control of nematodes of OPR3-sample gene
WO2008095970A1 (en) 2007-02-09 2008-08-14 Basf Plant Science Gmbh Compositions and methods using rna interference of cdpk-like for control of nematodes
WO2008118324A2 (en) 2007-03-26 2008-10-02 Macrogenics, Inc. Composition and method of treating cancer with an anti-uroplakin ib antibody
JP2011505144A (en) 2007-11-30 2011-02-24 ベイラー カレッジ オブ メディシン Dendritic cell vaccine composition and use thereof
WO2010046423A2 (en) 2008-10-22 2010-04-29 Basf Se Use of sulfonylurea herbicides on cultivated plants
AR075466A1 (en) 2008-10-22 2011-04-06 Basf Se USE OF AUXINE TYPE HERBICIDES IN CULTIVATED PLANTS
MX2011009415A (en) 2009-03-20 2011-09-27 Basf Plant Science Co Gmbh Nematode-resistant transgenic plants.
WO2011038002A1 (en) 2009-09-22 2011-03-31 Yale University Immunogenic epitopes as targets for universal cancer vaccines
US8993741B2 (en) 2009-11-17 2015-03-31 The Trustees Of The University Of Pennsylvania SMNdelta7 degron: novel compositions and methods of use
MX2012009033A (en) 2010-02-23 2012-11-23 Basf Plant Science Co Gmbh Nematode-resistant transgenic plants.
US9574204B2 (en) 2010-07-01 2017-02-21 E I Dupont De Nemours And Company Plant seeds with altered storage compound levels, related constructs and methods involving genes encoding PAE and PAE-like polypeptides
EP3327125B1 (en) 2010-10-29 2020-08-05 Sirna Therapeutics, Inc. Rna interference mediated inhibition of gene expression using short interfering nucleic acids (sina)
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
KR20140004174A (en) 2011-01-18 2014-01-10 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for treating cancer
CA2846486C (en) 2011-07-12 2019-08-20 Philadelphia Health & Education Corporation Novel clostridium difficile dna vaccine
ES2888651T3 (en) 2011-07-29 2022-01-05 Univ Pennsylvania costimulatory switching receptors
WO2013044225A1 (en) 2011-09-22 2013-03-28 The Trustees Of The University Of Pennsylvania A universal immune receptor expressed by t cells for the targeting of diverse and multiple antigens
EP2764101B1 (en) 2011-10-04 2017-03-29 Bayer Intellectual Property GmbH RNAi FOR THE CONTROL OF FUNGI AND OOMYCETES BY INHIBITING SACCHAROPINE DEHYDROGENASE GENE
US9272002B2 (en) 2011-10-28 2016-03-01 The Trustees Of The University Of Pennsylvania Fully human, anti-mesothelin specific chimeric immune receptor for redirected mesothelin-expressing cell targeting
US9422351B2 (en) 2011-11-03 2016-08-23 The Trustees Of The University Of Pennsylvania Isolated B7-H4 specific compositions and methods of use thereof
WO2013070468A1 (en) 2011-11-08 2013-05-16 The Trustees Of The University Of Pennsylvania Glypican-3-specific antibody and uses thereof
WO2013078230A1 (en) 2011-11-23 2013-05-30 The Trustees Of The University Of Pennsylvania Use of pdl1 expressing cells to convert t cells into regulatory t cells
KR20140127816A (en) 2012-02-22 2014-11-04 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
EP2817331B1 (en) 2012-02-22 2023-08-30 The Trustees of the University of Pennsylvania Use of the cd2 signaling domain in second-generation chimeric antigen receptors
CA3205751A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Use of icos-based cars to enhance antitumor activity and car persistence
EP4148135A1 (en) 2012-07-05 2023-03-15 The Trustees of the University of Pennsylvania U1 snrnp regulates gene expression and modulates oncogenicity
WO2014011996A1 (en) 2012-07-13 2014-01-16 The Trustees Of The University Of Pennsylvania Methods of assessing the suitability of transduced t cells for administration
KR20150029714A (en) 2012-07-13 2015-03-18 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Enhancing activity of car t cells by co-introducing a bispecific antibody
US9937205B2 (en) 2012-09-04 2018-04-10 The Trustees Of The University Of Pennsylvania Inhibition of diacylglycerol kinase to augment adoptive T cell transfer
BR112015004074A2 (en) 2012-10-01 2017-07-04 Basf Se method for controlling pests, use and seed of a cultivated plant.
TW201414837A (en) 2012-10-01 2014-04-16 Univ Pennsylvania Compositions and methods for calibrating stromal cells to treat cancer
US9598489B2 (en) 2012-10-05 2017-03-21 The Trustees Of The Univeristy Of Pennsylvania Human alpha-folate receptor chimeric antigen receptor
WO2014090765A1 (en) 2012-12-12 2014-06-19 Bayer Cropscience Ag Use of 1-[2-fluoro-4-methyl-5-(2,2,2-trifluoroethylsulfinyl)phenyl]-5-amino-3-trifluoromethyl)-1 h-1,2,4 tfia zole for controlling nematodes in nematode-resistant crops
EP2951199A4 (en) 2013-01-31 2016-07-20 Univ Jefferson FUSION PROTEINS FOR MODULATING LYMPHOCYTES T REGULATORS AND EFFECTORS
WO2015116178A1 (en) 2014-01-31 2015-08-06 Thomas Jefferson University Fusion proteins for modulating regulatory and effector t cells
WO2014130635A1 (en) 2013-02-20 2014-08-28 Novartis Ag Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
US9394368B2 (en) 2013-02-20 2016-07-19 Novartis Ag Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor
US8957044B2 (en) 2013-03-01 2015-02-17 Wake Forest University Health Sciences Systemic gene replacement therapy for treatment of X-linked myotubular myopathy (XLMTM)
US9446105B2 (en) 2013-03-15 2016-09-20 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor specific for folate receptor β
WO2014145252A2 (en) 2013-03-15 2014-09-18 Milone Michael C Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
JP6779785B2 (en) 2013-12-19 2020-11-04 ノバルティス アーゲー Human mesothelin chimeric antigen receptor and its use
US10287354B2 (en) 2013-12-20 2019-05-14 Novartis Ag Regulatable chimeric antigen receptor
WO2015112626A1 (en) 2014-01-21 2015-07-30 June Carl H Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
EP3593812A3 (en) 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3811970A1 (en) 2014-03-15 2021-04-28 Novartis AG Regulatable chimeric antigen receptor
DK3888674T3 (en) 2014-04-07 2024-07-08 Novartis Ag TREATMENT OF CANCER USING ANTI-CD19 CHIMERIC ANTIGEN RECEPTOR
ES2900327T3 (en) 2014-05-02 2022-03-16 Univ Pennsylvania Compositions and Methods of Chimeric Autoantibody Receptor T Cells
EP3791891A1 (en) 2014-07-17 2021-03-17 Brian J. Czerniecki Identification of immunogenic mhc class ii peptides for immune-based therapy
EP3193915A1 (en) 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
AU2015292744C1 (en) 2014-07-21 2021-01-21 Novartis Ag Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
SG11201700416TA (en) 2014-07-21 2017-02-27 Novartis Ag Treatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en) 2014-07-21 2023-01-03 Novartis Ag Sortase synthesized chimeric antigen receptors
WO2016019300A1 (en) 2014-07-31 2016-02-04 Novartis Ag Subset-optimized chimeric antigen receptor-containing t-cells
CA2958200A1 (en) 2014-08-14 2016-02-18 Novartis Ag Treatment of cancer using a gfr alpha-4 chimeric antigen receptor
WO2016028896A1 (en) 2014-08-19 2016-02-25 Novartis Ag Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
CN107580628B (en) 2014-09-17 2022-01-07 诺华股份有限公司 Targeted cytotoxic cells with chimeric receptors for adoptive immunotherapy
KR20170068504A (en) 2014-10-08 2017-06-19 노파르티스 아게 Biomarkers predictive of therapeutic responsiveness to chimeric antigen receptor therapy and uses thereof
US20180334490A1 (en) 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
WO2016091674A1 (en) 2014-12-12 2016-06-16 Basf Se Use of cyclaniliprole on cultivated plants
WO2016098078A2 (en) 2014-12-19 2016-06-23 Novartis Ag Dimerization switches and uses thereof
SG11201705293WA (en) 2014-12-29 2017-07-28 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
MA41349A (en) 2015-01-14 2017-11-21 Univ Temple RNA-GUIDED ERADICATION OF HERPES SIMPLEX TYPE I AND OTHER ASSOCIATED HERPES VIRUSES
GB201501004D0 (en) 2015-01-21 2015-03-04 Cancer Rec Tech Ltd Inhibitors
US11161907B2 (en) 2015-02-02 2021-11-02 Novartis Ag Car-expressing cells against multiple tumor antigens and uses thereof
CN114891816B (en) 2015-02-06 2025-01-21 新加坡国立大学 Nucleic acid, engineered immune cell containing the same, and preparation method and use thereof
EP3261651B1 (en) 2015-02-27 2022-05-04 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars) targeting hematologic malignancies, compositions and methods of use thereof
MA41629A (en) 2015-03-04 2018-01-09 Center For Human Reproduction COMPOSITIONS AND METHODS OF USE OF ANTI-MÜLLERIAN HORMONE FOR THE TREATMENT OF INFERTILITY
WO2016145578A1 (en) 2015-03-13 2016-09-22 Syz Cell Therapy Co. Methods of cancer treatment using activated t cells
MX2017012352A (en) 2015-04-03 2018-01-26 Eureka Therapeutics Inc CONSTRUCTION DIRECTED TO ALFA-PHETOPROTEIN PEPTIDE COMPLEX / MAIN HISTOCOMPATIBILITY COMPLEX (AFP / CPH) AND USES OF THE SAME.
ES2901273T3 (en) 2015-04-06 2022-03-21 Subdomain Llc De novo binding domain-containing polypeptides and uses thereof
ES2876974T3 (en) 2015-04-07 2021-11-15 Novartis Ag Combination therapy with chimeric antigen receptor and amino pyrimidine derivatives
WO2016162371A1 (en) 2015-04-07 2016-10-13 Basf Agrochemical Products B.V. Use of an insecticidal carboxamide compound against pests on cultivated plants
PT3280729T (en) 2015-04-08 2022-08-01 Novartis Ag Cd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
SG11201708516YA (en) 2015-04-17 2017-11-29 David Maxwell Barrett Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
WO2016170484A1 (en) 2015-04-21 2016-10-27 Novartis Ag Rna-guided gene editing system and uses thereof
US12128069B2 (en) 2015-04-23 2024-10-29 The Trustees Of The University Of Pennsylvania Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
WO2016174652A1 (en) 2015-04-30 2016-11-03 Technion Research & Development Foundation Limited Chimeric antigen receptors and methods of their use
US10925972B2 (en) 2015-05-01 2021-02-23 The Regents Of The University Of California Glycan-dependent immunotherapeutic molecules
SG10201914069SA (en) 2015-05-18 2020-03-30 Tcr2 Therapeutics Inc Compositions and methods for tcr reprogramming using fusion proteins
EP3932428A1 (en) 2015-05-21 2022-01-05 Harpoon Therapeutics, Inc. Trispecific binding proteins and methods of use
SG10201913682QA (en) 2015-06-25 2020-03-30 Icell Gene Therapeutics Llc CHIMERIC ANTIGEN RECEPTORS (CARs), COMPOSITIONS AND METHODS OF USE THEREOF
PL3322424T3 (en) 2015-07-16 2024-03-04 Yeda Research And Development Co., Ltd. USING CENTRAL MEMORY T LYMPHOCYTES AGAINST THE THIRD PARTY
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
EP3340998B1 (en) 2015-08-28 2023-01-11 The Trustees of the University of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
JP6905163B2 (en) 2015-09-03 2021-07-21 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Biomarkers that predict cytokine release syndrome
MX2018003463A (en) 2015-09-22 2018-09-06 Univ Pennsylvania Method of redirecting t cells to treat hiv infection.
SG11201802895QA (en) 2015-10-23 2018-05-30 Eureka Therapeutics Inc Antibody/t-cell receptor chimeric constructs and uses thereof
JP7023842B2 (en) 2015-10-29 2022-02-22 テンプル ユニヴァーシティ － オブ ザ コモンウェルス システム オブ ハイアー エデュケーション Modification of the 3'end of nucleic acid with DNA polymerase theta
AU2016343805A1 (en) 2015-10-30 2018-06-07 Aleta Biotherapeutics Inc. Compositions and methods for tumor transduction
JP7115982B2 (en) 2015-10-30 2022-08-09 アレタ・バイオセラピューティクス・インコーポレイテッド Compositions and methods for treating cancer
AU2016361451B2 (en) 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
CA3006759A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2017112741A1 (en) 2015-12-22 2017-06-29 Novartis Ag Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
JP2019500874A (en) 2015-12-28 2019-01-17 ノバルティス アーゲー Method for producing chimeric antigen receptor-expressing cells
WO2017118726A1 (en) 2016-01-06 2017-07-13 Lonza Ltd Inhibition of protein degradation for improved production
US11441146B2 (en) 2016-01-11 2022-09-13 Christiana Care Health Services, Inc. Compositions and methods for improving homogeneity of DNA generated using a CRISPR/Cas9 cleavage system
SG11201807489PA (en) 2016-03-04 2018-09-27 Novartis Ag Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
BR112018068281A2 (en) 2016-03-10 2019-04-02 Lonza Ag customizable installation
US10689873B2 (en) 2016-03-10 2020-06-23 Lonza Ltd Customizable facility
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
RU2018137110A (en) 2016-04-13 2020-05-13 Оримабс Лтд. ANTIBODIES AGAINST PSMA AND THEIR APPLICATION
CN109564217A (en) 2016-04-14 2019-04-02 隆扎有限公司 For detecting the composition and method of host cell proteins
PT3443096T (en) 2016-04-15 2023-05-30 Novartis Ag Compositions and methods for selective protein expression
JP2019513394A (en) 2016-04-15 2019-05-30 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Compositions and methods of chimeric alloantigen receptor T cells
US20190119364A1 (en) 2016-04-29 2019-04-25 The Regents Of The University Of Colorado, A Body Corporate Compounds and compositions useful for treating metabolic syndrome, and methods using same
KR102536221B1 (en) 2016-05-03 2023-05-23 론자 리미티드 Modulation of lipid metabolism for protein production
CA3024723A1 (en) 2016-05-20 2017-11-23 Robert B. Dubridge Single domain serum albumin binding protein
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
EP3464375A2 (en) 2016-06-02 2019-04-10 Novartis AG Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
EP3468994A1 (en) 2016-06-08 2019-04-17 Intrexon Corporation Cd33 specific chimeric antigen receptors
CN109562126A (en) 2016-06-24 2019-04-02 美商生物细胞基因治疗有限公司 Chimeric antigen receptor (CAR), composition and its application method
AU2017295886C1 (en) 2016-07-15 2024-05-16 Novartis Ag Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
CN109477114A (en) 2016-07-18 2019-03-15 赫利克斯生物药品公司 CAR immune cells targeting carcinoembryonic antigen-related cell adhesion molecule 6 for the treatment of cancer
KR20190034588A (en) 2016-07-28 2019-04-02 노파르티스 아게 Combination therapy of chimeric antigen receptor and PD-1 inhibitor
EP3490590A2 (en) 2016-08-01 2019-06-05 Novartis AG Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
JP2019525765A (en) 2016-08-02 2019-09-12 ロンザ リミテッドＬｏｎｚａ Ｌｉｍｉｔｅｄ Customizable facilities
WO2018026953A1 (en) 2016-08-02 2018-02-08 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CN109891244A (en) 2016-08-12 2019-06-14 隆扎有限公司 To the Proteomic analysis of host cell proteins matter
EP3516068A4 (en) 2016-09-19 2020-10-14 University of Southern California NON-RADIOACTIVE CYTOTOXICITY TESTS
DK3757120T3 (en) 2016-10-04 2022-07-25 Prec Biosciences Inc CO-STIMULATORY DOMAINS FOR USE IN GENETICALLY MODIFIED CELLS
HUE054080T2 (en) 2016-10-07 2021-08-30 Tcr2 Therapeutics Inc Compositions and methods for reprogramming T cell receptors using fusion proteins
CA3039646A1 (en) 2016-10-07 2018-04-12 Novartis Ag Chimeric antigen receptors for the treatment of cancer
EP4124343A1 (en) 2016-10-20 2023-02-01 I-Mab Biopharma US Limited Novel cd47 monoclonal antibodies and uses thereof
US20180245065A1 (en) 2016-11-01 2018-08-30 Novartis Ag Methods and compositions for enhancing gene editing
JP2019536480A (en) 2016-11-22 2019-12-19 ナショナル ユニバーシティ オブ シンガポール Blockade of CD7 expression and chimeric antigen receptor for immunotherapy of T cell malignancies
CA3044593A1 (en) 2016-11-22 2018-05-31 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
CA3044659A1 (en) 2016-11-23 2018-05-31 Harpoon Therapeutics, Inc. Prostate specific membrane antigen binding protein
EP3544629A4 (en) 2016-11-23 2020-06-17 Harpoon Therapeutics, Inc. PSMA TO BE TRISPECIFIC PROTEINS AND METHOD FOR USE THEREOF
WO2018119298A1 (en) 2016-12-21 2018-06-28 TCR2 Therapeutics Inc. Engineered t cells for the treatment of cancer
WO2018127585A1 (en) 2017-01-06 2018-07-12 Txcell Monospecific regulatory t cell population with cytotoxicity for b cells
EP3346001A1 (en) 2017-01-06 2018-07-11 TXCell Monospecific regulatory t cell population with cytotoxicity for b cells
JP7308380B2 (en) 2017-01-10 2023-07-14 クリスティアーナ ケア ジーン エディティング インスティテュート，インコーポレイテッド Methods for in vitro site-directed mutagenesis using gene editing technology
JP7288401B2 (en) 2017-01-10 2023-06-07 プレシゲン，インコーポレイテッド Modulation of polypeptide expression via a novel gene switch expression system
TW201831517A (en) 2017-01-12 2018-09-01 美商優瑞科生物技術公司 Construct for targeting tissue protein H3 peptide/MHC complex and use thereof
IL268126B2 (en) 2017-01-18 2024-02-01 Yeda Res & Dev Genetically modified veto cells and use of same in immunotherapy
EP3574005B1 (en) 2017-01-26 2021-12-15 Novartis AG Cd28 compositions and methods for chimeric antigen receptor therapy
CN108395482B (en) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 Construction of targeting CD20 antigen chimeric antigen receptor and activity identification of engineered T cell thereof
EP3585880A1 (en) 2017-02-27 2020-01-01 Life Technologies Corporation Expansion of populations of t cells by the use of modified serum free media
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
US11590202B2 (en) 2017-04-11 2023-02-28 University Of Maryland, Baltimore Inhibitors of LTβR-NFκB signaling pathways for treating inflammation and cancer
WO2018191490A1 (en) 2017-04-13 2018-10-18 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
CN110741016A (en) 2017-04-26 2020-01-31 优瑞科生物技术公司 Chimeric antibody/T-cell receptor constructs and uses thereof
CA3059820A1 (en) 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Constructs specifically recognizing glypican 3 and uses thereof
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CA3062698A1 (en) 2017-05-08 2018-11-15 Precision Biosciences, Inc. Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof
IL300964A (en) 2017-05-12 2023-04-01 Harpoon Therapeutics Inc Mesothelin binding proteins
US10730954B2 (en) 2017-05-12 2020-08-04 Harpoon Therapeutics, Inc. MSLN targeting trispecific proteins and methods of use
US20210079057A1 (en) 2017-06-13 2021-03-18 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
KR102647165B1 (en) 2017-06-16 2024-03-14 론자 리미티드 A universal self-regulating mammalian cell line platform for biologics production
EP3648789B9 (en) 2017-07-03 2023-09-27 Université de Strasbourg Mtmr2-s polypeptide for use in the treatment of myopathies
CN109456943A (en) 2017-09-06 2019-03-12 亘喜生物科技（上海）有限公司 Universal Chimeric antigen receptor T cell technology of preparing
WO2019055853A1 (en) 2017-09-15 2019-03-21 Life Technologies Corporation Compositions and methods for culturing and expanding cells
EP3684821A4 (en) 2017-09-19 2021-06-16 The University Of British Columbia Anti-hla-a2 antibodies and methods of using the same
AU2018338423A1 (en) 2017-09-20 2020-04-09 Sangamo Therapeutics France Novel anti-HLA-A2 antibodies and uses thereof
CN109554348A (en) 2017-09-27 2019-04-02 亘喜生物科技（上海）有限公司 It can induce the engineering immunocyte of secretion anti-cd 47 antibody
EP3692057B9 (en) 2017-10-03 2023-10-04 Precision BioSciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
CN118497126A (en) 2017-10-04 2024-08-16 赫斯佩瑞克斯股份公司 Articles and methods for personalized cancer therapy
WO2019069125A1 (en) 2017-10-06 2019-04-11 Oslo Universitetssykehus Hf Chimeric antigen receptors
EP3694536A4 (en) 2017-10-12 2021-08-18 The Regents of The University of California CELL-BASED IMPFASSAY FOR THE HUNTINGTON AGGREGATION
IL315737A (en) 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B cell maturation antigen binding proteins
KR102569133B1 (en) 2017-10-13 2023-08-21 하푼 테라퓨틱스, 인크. Trispecific proteins and methods of use
US20200370012A1 (en) 2017-10-25 2020-11-26 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2019089798A1 (en) 2017-10-31 2019-05-09 Novartis Ag Anti-car compositions and methods
US11666628B2 (en) 2017-11-11 2023-06-06 Universite De Strasbourg Compositions and method for the treatment of x-linked centronuclear myopathy
MX2020004933A (en) 2017-11-14 2021-01-08 Arcellx Inc D-domain containing polypeptides and uses thereof.
MX2020004935A (en) 2017-11-14 2020-09-25 Arcellx Inc Multifunctional immune cell therapies.
MX2020004948A (en) 2017-11-15 2020-11-11 Novartis Ag TARGETING CHIMERIC ANTIGEN RECEPTOR BCMA, TARGETING CHIMERIC ANTIGEN RECEPTOR CD19 AND COMBINATION THERAPIES.
KR20200096253A (en) 2017-11-30 2020-08-11 노파르티스 아게 BCMA-targeting chimeric antigen receptor, and uses thereof
US20210178289A1 (en) 2017-12-05 2021-06-17 Lonza Ltd Methods of assaying tropolone
JP7372920B2 (en) 2017-12-29 2023-11-01 セレクティス Methods for improving the generation of CAR T cells
TW201930591A (en) 2018-01-08 2019-08-01 瑞士商諾華公司 Immune-enhancing RNAs for combination with chimeric antigen receptor therapy
US12215154B2 (en) 2018-01-19 2025-02-04 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting γδ T cells with chimeric antigen receptors
GB201801067D0 (en) 2018-01-23 2018-03-07 Price Nicola Kaye Biomarkers predictive of tumour infiltrating lymphocyte therapy and uses thereof
AU2019215031A1 (en) 2018-01-31 2020-08-20 Novartis Ag Combination therapy using a chimeric antigen receptor
JP7108036B2 (en) 2018-02-02 2022-07-27 ロンザ リミテッド Cell selection method and cell metabolism modification method
JP2021513367A (en) 2018-02-12 2021-05-27 ダイアベーツ−フリー， インコーポレイテッド Improved antagonistic anti-human CD40 monoclonal antibody
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
JP2021515583A (en) 2018-03-14 2021-06-24 ベイジン シュアンイー ファーマサイエンシーズ カンパニー， リミテッド Anti-claudin 18.2 antibody
WO2019183924A1 (en) 2018-03-30 2019-10-03 Syz Cell Therapy Co. Improved multiple antigen specific cell therapy methods
CN110372796B (en) 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 Chimeric antigen receptor targeting BCMA and preparation method and application thereof
WO2019196087A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of cancer treatment using tumor antigen-specific t cells
WO2019196088A1 (en) 2018-04-13 2019-10-17 Syz Cell Therapy Co. Methods of obtaining tumor-specific t cell receptors
SG11202010116PA (en) 2018-04-13 2020-11-27 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
WO2019210153A1 (en) 2018-04-27 2019-10-31 Novartis Ag Car t cell therapies with enhanced efficacy
US10874750B2 (en) 2018-04-30 2020-12-29 Amicus Therapeutics, Inc. Gene therapy constructs and methods of use
EP3788369A1 (en) 2018-05-01 2021-03-10 Novartis Ag Biomarkers for evaluating car-t cells to predict clinical outcome
AU2019262131A1 (en) 2018-05-02 2020-11-19 The Trustees Of The University Of Pennsylvania Compositions and methods of phospholipase A2 receptor chimeric autoantibody receptor T cells
EP3790958A1 (en) 2018-05-08 2021-03-17 Life Technologies Corporation Compositions and methods for culturing and expanding cells
EP3801769A1 (en) 2018-05-25 2021-04-14 Novartis AG Combination therapy with chimeric antigen receptor (car) therapies
US11608382B2 (en) 2018-06-13 2023-03-21 Novartis Ag BCMA chimeric antigen receptors and uses thereof
WO2019241549A1 (en) 2018-06-15 2019-12-19 A2 Biotherapeutics, Inc. Foxp3-expressing car-t regulatory cells
US11993661B2 (en) 2018-06-18 2024-05-28 Eureka Therapeutics, Inc. Constructs targeting prostate-specific membrane antigen (PSMA) and uses thereof
GB201810181D0 (en) 2018-06-21 2018-08-08 Immetacyte Ltd Cells expressing chimeric recominant growth factor receptors
MX2021001592A (en) 2018-08-10 2021-09-21 Sangamo Therapeutics France NEW CAR BUILDS INCLUDING TNFR2 DOMAINS.
CN112584863A (en) 2018-08-17 2021-03-30 Ab工作室有限公司 Catalytic antibodies and methods of use thereof
KR20210069048A (en) 2018-08-30 2021-06-10 티씨알2 테라퓨틱스 인크. Compositions and methods for TCR reprogramming using fusion proteins
CN112639083A (en) 2018-08-31 2021-04-09 诺华股份有限公司 Method for producing cells expressing chimeric antigen receptor
EP3843778A1 (en) 2018-08-31 2021-07-07 Invectys Sa Chimeric antigen receptors against multiple hla-g isoforms
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
EP3856782A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
EP3856779A1 (en) 2018-09-28 2021-08-04 Novartis AG Cd22 chimeric antigen receptor (car) therapies
AU2019359385B2 (en) 2018-10-10 2024-07-25 Amicus Therapeutics, Inc. Disulfide bond stabilized polypeptide compositions and methods of use
US12186590B2 (en) 2018-10-19 2025-01-07 University Of Rochester Immune modulators in combination with radiation treatment for advanced pancreatic cancer
US20210363509A1 (en) 2018-10-22 2021-11-25 University Of Rochester Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas9 Fusion Protein
US20220170097A1 (en) 2018-10-29 2022-06-02 The Broad Institute, Inc. Car t cell transcriptional atlas
WO2020102454A1 (en) 2018-11-13 2020-05-22 Regents Of The University Of Minnesota Cd40 targeted peptides and uses thereof
PL3880802T3 (en) 2018-11-16 2023-03-06 Celgene Corporation Improved way to produce T cells
JP7627216B2 (en) 2018-11-16 2025-02-05 メモリアル スローン ケタリング キャンサー センター Antibodies to mucin-16 and methods of using same - Patents.com
US20220089670A1 (en) 2018-12-28 2022-03-24 University Of Rochester Gene Therapy for BEST1 Dominant Mutations
WO2020150287A1 (en) 2019-01-14 2020-07-23 University Of Rochester Targeted nuclear rna cleavage and polyadenylation with crispr-cas
GB201900858D0 (en) 2019-01-22 2019-03-13 Price Nicola Kaye Receptors providing targeted costimulation for adoptive cell therapy
WO2020161186A1 (en) 2019-02-08 2020-08-13 Biontech Cell & Gene Therapies Gmbh Chimeric antigen receptor-modified cells for the treatment of cldn6-expressing cancers
WO2020172553A1 (en) 2019-02-22 2020-08-27 Novartis Ag Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
RU2742000C2 (en) 2019-03-13 2021-02-01 Общество С Ограниченной Ответственностью "Анабион" Isolated alternative intracellular signalling domain of chimeric antigen receptor and chimeric antigen receptor including it
JP7379654B2 (en) 2019-03-15 2023-11-14 カーティザン セラピューティクス，インコーポレーテッド Anti-BCMA chimeric antigen receptor
JP2022525944A (en) 2019-03-20 2022-05-20 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィック Amphifidine / BIN1 for treating autosomal dominant core myopathy
US11090336B2 (en) 2019-03-27 2021-08-17 The Trustees Of The University Of Pennsylvania Tn-MUC1 chimeric antigen receptor (CAR) T cell therapy
EP3953455A1 (en) 2019-04-12 2022-02-16 Novartis AG Methods of making chimeric antigen receptor-expressing cells
EP3959320A1 (en) 2019-04-24 2022-03-02 Novartis AG Compositions and methods for selective protein degradation
TW202110873A (en) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 Chimeric receptors and methods of use thereof
WO2020224606A1 (en) 2019-05-07 2020-11-12 亘喜生物科技（上海）有限公司 Engineered immune cell targeting bcma and use thereof
CA3145662A1 (en) 2019-07-02 2021-01-07 M6P Therapeutics Vector compositions and methods of using same for treatment of lysosomal storage disorders
US20220267773A1 (en) 2019-07-23 2022-08-25 University Of Rochester Targeted RNA cleavage with CRISPR-Cas
WO2021016608A1 (en) 2019-07-25 2021-01-28 Precision Biosciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
CN112300997A (en) 2019-08-01 2021-02-02 上海赛比曼生物科技有限公司 Universal CAR-T cell and its preparation and application
WO2021030182A1 (en) 2019-08-09 2021-02-18 A2 Biotherapeutics, Inc. Bifunctional single variable domain t cell receptors and uses thereof
CN114269907A (en) 2019-08-19 2022-04-01 巴塞尔大学 Cell therapy method
CA3148179A1 (en) 2019-08-20 2021-02-25 Bruce J. Mccreedy Jr. Lymphodepletion dosing regimens for cellular immunotherapies
WO2021035170A1 (en) 2019-08-21 2021-02-25 Precision Biosciences, Inc. Compositions and methods for tcr reprogramming using fusion proteins
EP3808766A1 (en) 2019-10-15 2021-04-21 Sangamo Therapeutics France Chimeric antigen receptor specific for interleukin-23 receptor
US20220389075A1 (en) 2019-11-12 2022-12-08 A2 Biotherapeutics, Inc. Engineered t cell receptors and uses thereof
IL292890A (en) 2019-11-14 2022-07-01 Lonza Ag Methods for selecting cells
CN115925976A (en) 2019-11-21 2023-04-07 博生吉医药科技(苏州)有限公司 CD7-CAR-T cell and preparation and application thereof
WO2021108613A1 (en) 2019-11-26 2021-06-03 Novartis Ag Cd19 and cd22 chimeric antigen receptors and uses thereof
AR120566A1 (en) 2019-11-26 2022-02-23 Novartis Ag CHIMERIC ANTIGEN RECEPTORS AND THEIR USES
KR20220124173A (en) 2019-12-11 2022-09-13 에이투 바이오쎄라퓨틱스, 인크. LILRB1-based chimeric antigen receptor
CA3168903A1 (en) 2020-02-07 2021-08-12 University Of Rochester Ribozyme-mediated rna assembly and expression
US20230078498A1 (en) 2020-02-07 2023-03-16 University Of Rochester Targeted Translation of RNA with CRISPR-Cas13 to Enhance Protein Synthesis
US20230111593A1 (en) 2020-02-14 2023-04-13 Novartis Ag Method of predicting response to chimeric antigen receptor therapy
CN115768463A (en) 2020-02-21 2023-03-07 哈普恩治疗公司 FLT 3-binding proteins and methods of use
WO2021173674A1 (en) 2020-02-26 2021-09-02 A2 Biotherapeutics, Inc. Polypeptides targeting mage-a3 peptide-mhc complexes and methods of use thereof
US20230174933A1 (en) 2020-02-27 2023-06-08 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN115175695A (en) 2020-02-27 2022-10-11 诺华股份有限公司 Method for producing cells expressing chimeric antigen receptor
CN115066440A (en) 2020-02-28 2022-09-16 上海复宏汉霖生物技术股份有限公司 anti-CD 137 constructs and uses thereof
CN115151573A (en) 2020-02-28 2022-10-04 上海复宏汉霖生物技术股份有限公司 anti-CD 137 constructs, multispecific antibodies, and uses thereof
CN113402612A (en) 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 Combined chimeric antigen receptor targeting CD19 and CD20 and application thereof
EP4121115A1 (en) 2020-03-19 2023-01-25 Trizell Ltd. Temperature-responsive virus storage system
BR112022018795A2 (en) 2020-03-20 2023-01-10 Inst Nat Sante Rech Med SPECIFIC CHIMERIC ANTIGEN RECEPTOR FOR HUMAN CD45RC AND USES THEREOF
EP4127170A1 (en) 2020-03-27 2023-02-08 University of Rochester Crispr-cas13 crrna arrays
EP4127169A1 (en) 2020-03-27 2023-02-08 University of Rochester Targeted destruction of viral rna by crispr-cas13
CN113527507A (en) 2020-04-16 2021-10-22 上海赛比曼生物科技有限公司 Chimeric antigen receptor targeting CD22 and preparation method and application thereof
WO2021222576A1 (en) 2020-05-01 2021-11-04 A2 Biotherapeutics, Inc. Pag1 fusion proteins and methods of making and using same
EP4157881A4 (en) 2020-05-27 2024-10-09 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibodies specifically recognizing nerve growth factor and uses thereof
WO2021252635A1 (en) 2020-06-11 2021-12-16 A2 Biotherapeutics, Inc. Compositions and methods for treating cancers
EP4165169A1 (en) 2020-06-11 2023-04-19 Novartis AG Zbtb32 inhibitors and uses thereof
CA3185589A1 (en) 2020-07-15 2022-01-20 Douglas Matthew ANDERSON Targeted rna cleavage with dcasl3-rnase fusion proteins
EP4183872A4 (en) 2020-07-16 2024-05-01 Shanghai Jiaotong University Immunotherapy method of targeted chemokine and cytokine delivery by mesenchymal stem cell
WO2022016114A1 (en) 2020-07-17 2022-01-20 Instill Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
AU2021308702A1 (en) 2020-07-17 2023-03-16 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
US20230330227A1 (en) 2020-08-13 2023-10-19 A2 Biotherapeutics, Inc. Gene fusions for control of genetically modified cells
JP7634653B2 (en) 2020-08-20 2025-02-21 エー２ バイオセラピューティクス， インコーポレイテッド Compositions and methods for treating mesothelin-positive cancer
FI4058474T3 (en) 2020-08-20 2024-07-01 A2 Biotherapeutics Inc Compositions and methods for treating EGFR-positive cancers
IL300497A (en) 2020-08-20 2023-04-01 A2 Biotherapeutics Inc Compositions and methods for treating ceacam positive cancers
US11999964B2 (en) 2020-08-28 2024-06-04 California Institute Of Technology Synthetic mammalian signaling circuits for robust cell population control
WO2022079308A1 (en) 2020-10-16 2022-04-21 Institut Pasteur Chimeric constructs useful in vaccination and cancer therapy
AU2021378316A1 (en) 2020-11-13 2023-06-01 Novartis Ag Combination therapies with chimeric antigen receptor (car)-expressing cells
CN114525306B (en) 2020-11-23 2025-01-28 博生吉医药科技(苏州)有限公司 A preparation method and application of CD7-CAR-T cells
TW202237638A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
TW202237639A (en) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 Compositions of guanylyl cyclase c (gcc) antigen binding agents and methods of use thereof
WO2022147463A2 (en) 2020-12-31 2022-07-07 Alamar Biosciences, Inc. Binder molecules with high affinity and/ or specificity and methods of making and use thereof
CN114763381B (en) 2021-01-13 2025-01-28 博生吉医药科技(苏州)有限公司 B7-H3 chimeric antigen receptor modified T cells and their applications
EP4277651A1 (en) 2021-01-15 2023-11-22 University of Rochester <smallcaps/>? ? ?staphylococcus? ? ? ? ?aureus antigen-based nucleic acid vaccines
EP4284823A1 (en) 2021-01-28 2023-12-06 Precision BioSciences, Inc. Modulation of tgf beta signaling in genetically-modified eukaryotic cells
GB2603166A (en) 2021-01-29 2022-08-03 Thelper As Therapeutic and Diagnostic Agents and Uses Thereof
CN114907485B (en) 2021-02-08 2024-04-26 浙江大学 A chimeric antigen receptor that replaces a single-domain antibody with an endogenous protein molecule
CN117597358A (en) 2021-02-16 2024-02-23 A2生物治疗股份有限公司 Compositions and methods for treating HER2 positive cancers
US20240181084A1 (en) 2021-04-23 2024-06-06 University Of Rochester Genome Editing by Directed Non-Homologous DNA Insertion Using a Retroviral Integrase-Cas Fusion Protein and Methods of Treatment
TW202307210A (en) 2021-06-01 2023-02-16 瑞士商諾華公司 Cd19 and cd22 chimeric antigen receptors and uses thereof
CN115477704B (en) 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on LOX1
US11945876B2 (en) 2021-06-16 2024-04-02 Instil Bio (Uk) Limited Receptors providing targeted costimulation for adoptive cell therapy
CN115477705B (en) 2021-06-16 2024-02-23 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on granzyme B
EP4355785A1 (en) 2021-06-17 2024-04-24 Amberstone Biosciences, Inc. Anti-cd3 constructs and uses thereof
WO2022271955A1 (en) 2021-06-23 2022-12-29 Musc Foundation For Research Development Novel targeted shrna nanoparticles for cancer therapy
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202317633A (en) 2021-07-08 2023-05-01 美商舒泰神（加州）生物科技有限公司 Antibodies specifically recognizing tnfr2 and uses thereof
EP4371572A1 (en) 2021-07-14 2024-05-22 Staidson (Beijing) Biopharmaceuticals Co., Ltd. Antibody that specifically recognizes cd40 and application thereof
WO2023288278A1 (en) 2021-07-16 2023-01-19 Instil Bio (Uk) Limited Chimeric molecules providing targeted costimulation for adoptive cell therapy
CN115873802A (en) 2021-09-29 2023-03-31 亘喜生物科技（上海）有限公司 Chimeric antigen receptor immune cell and its preparation method and application
IL311572A (en) 2021-09-30 2024-05-01 Akouos Inc Compositions and methods for treating kcnq4-associated hearing loss
JP2024540971A (en) 2021-10-20 2024-11-06 ユニバーシティ オブ ロチェスター Isolated glial progenitor cells for use in the competitive treatment of age-related white matter loss
US20230270818A1 (en) 2021-11-02 2023-08-31 University Of Rochester Tcf7l2 mediated remyelination in the brain
CN116102658A (en) 2021-11-09 2023-05-12 四川大学华西医院 Preparation and application of chimeric antigen receptor immune cells constructed based on GAS6
US20250034533A1 (en) 2021-11-12 2025-01-30 Amicus Therapeutics, Inc. Compositions And Methods For Treating Mucopolysaccharidosis IIIA
WO2023091954A2 (en) 2021-11-19 2023-05-25 The Trustees Of The University Of Pennsylvania Engineered pan-leukocyte antigen cd45 to facilitate car t cell therapy
WO2023089556A1 (en) 2021-11-22 2023-05-25 Pfizer Inc. Reducing risk of antigen mimicry in immunogenic medicaments
CN116829179A (en) 2021-12-06 2023-09-29 北京三诺佳邑生物技术有限责任公司 Bispecific antibodies and compositions that specifically bind Klebsiella pneumoniae O2 antigen and O1 antigen
AU2022405694A1 (en) 2021-12-09 2024-07-04 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
WO2024046572A1 (en) 2022-09-01 2024-03-07 BioNTech SE Chimeric antigen receptor-modified cells for the treatment of cldn6 expressing cancer
AU2022424159A1 (en) 2021-12-29 2024-08-01 Shanghai Cell Therapy Group Co., Ltd Anti-mesothelin nanobody chimeric antigen receptor and use thereof
GB202201137D0 (en) 2022-01-28 2022-03-16 Thelper As Therapeutic and diagnostic agents and uses thereof
JP2025504887A (en) 2022-01-28 2025-02-19 ファイザー・インク Coronavirus antigen variants
EP4493581A1 (en) 2022-03-18 2025-01-22 University of Rochester Combination therapy for treatment of cancer, methods and systems of delivery thereof
WO2023215860A1 (en) 2022-05-05 2023-11-09 University Of Rochester Modified bacteria and methods of use for bioglass microlenses
WO2023217068A1 (en) 2022-05-09 2023-11-16 舒泰神（北京）生物制药股份有限公司 Antibody that specifically recognizes gdf15 and use thereof
WO2024020407A1 (en) 2022-07-19 2024-01-25 Staidson Biopharma Inc. Antibodies specifically recognizing b- and t-lymphocyte attenuator (btla) and uses thereof
AU2023342547A1 (en) 2022-09-15 2025-03-06 Novartis Ag Treatment of autoimmune disorders using chimeric antigen receptor therapy
WO2024091824A1 (en) 2022-10-26 2024-05-02 Ada Forsyth Institute, Inc. Differentiation and reprogramming of chondrocyte
WO2024121380A1 (en) 2022-12-08 2024-06-13 Pierre Fabre Medicament Vaccinal composition and adjuvant
WO2024133052A1 (en) 2022-12-19 2024-06-27 Universität Basel Vizerektorat Forschung T-cell receptor fusion protein
WO2024133600A1 (en) 2022-12-20 2024-06-27 Nanocell Therapeutics B.V. Integrating and self-inactivating viral vectors and constructs and uses thereof
WO2024163747A2 (en) 2023-02-02 2024-08-08 University Of Rochester Competitive replacement of glial cells
WO2024191808A1 (en) 2023-03-10 2024-09-19 University Of Rochester Etiological therapeutics for fragile x syndrome
WO2024188355A1 (en) 2023-03-16 2024-09-19 Itabmed Biopharmaceutical (Shanghai) Co., Ltd. Multispecific antigen binding proteins and uses thereof
WO2024196855A2 (en) 2023-03-17 2024-09-26 University Of Rochester Ribozyme-mediated rna assembly and expression
US20240350620A1 (en) 2023-04-24 2024-10-24 Centre For Virology, Vaccinology And Therapeutics Limited Ribonucleoprotein nanocomplex vaccines and uses thereof
CN119265241A (en) 2023-06-30 2025-01-07 深圳菁童生命科学有限公司 A method for rejuvenating cells by initiation phase reprogramming mediated by transcription factors without phase separation
WO2025027492A1 (en) 2023-07-31 2025-02-06 Pfizer Inc. Coronavirus antigen variants
US20250064855A1 (en) 2023-08-10 2025-02-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Use of dual-target CAR-T cells in treating B-cell autoimmune diseases
WO2025038492A1 (en) 2023-08-11 2025-02-20 Abalytics Oncology, Inc. Anti-ctla-4 antibodies and related binding molecules and methods and uses thereof
WO2025046513A1 (en) 2023-08-29 2025-03-06 Inceptor Bio, Llc Methods of manufacturing myeloid-derived cells from hematopoietic stem cells and compositions and uses thereof
WO2025045251A2 (en) 2023-09-03 2025-03-06 Kira Pharmaceuticals (Us) Llc Multispecific constructs comprising anti-factor d moiety
WO2025054500A2 (en) 2023-09-08 2025-03-13 Mlab Biosciences, Inc. Bifunctional proteins and uses thereof
WO2025072604A1 (en) 2023-09-28 2025-04-03 University Of Rochester Rna-editing gene therapy approaches for treating myotonic dystrophy type 1 (dm1)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017054A1 (en) * 1991-03-26 1992-10-15 Mogen International N.V. Method for the isolation and/or testing of genes and promoters involved in plant-nematode interactions using plants of the genus arabidopsis
WO1993010251A1 (en) * 1991-11-20 1993-05-27 Mogen International N.V. A method for obtaining plants with reduced susceptibility to plant-parasitic nematodes
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2000001846A2 (en) * 1998-07-03 2000-01-13 Devgen N.V. Characterisation of gene function using double stranded rna inhibition
WO2001037654A2 (en) * 1999-11-24 2001-05-31 Dna Plant Technology Corporation METHOD OF EXPRESSING dsRNA IN PLANTS TO INHIBIT INSECT PESTS

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992017054A1 (en) * 1991-03-26 1992-10-15 Mogen International N.V. Method for the isolation and/or testing of genes and promoters involved in plant-nematode interactions using plants of the genus arabidopsis
WO1993010251A1 (en) * 1991-11-20 1993-05-27 Mogen International N.V. A method for obtaining plants with reduced susceptibility to plant-parasitic nematodes
WO1999032619A1 (en) * 1997-12-23 1999-07-01 The Carnegie Institution Of Washington Genetic inhibition by double-stranded rna
WO2000001846A2 (en) * 1998-07-03 2000-01-13 Devgen N.V. Characterisation of gene function using double stranded rna inhibition
WO2001037654A2 (en) * 1999-11-24 2001-05-31 Dna Plant Technology Corporation METHOD OF EXPRESSING dsRNA IN PLANTS TO INHIBIT INSECT PESTS

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BASS BRENDA L: "Double-stranded RNA as a template for gene silencing.", CELL, vol. 101, no. 3, 28 April 2000 (2000-04-28), pages 235 - 238, XP002194756, ISSN: 0092-8674 *
NIEBEL ET AL: "induction of cdc2a and cyc1at expression in Arabidopsis thaliana during early phases of nematode-induced feeding cell formation", PLANT JOURNAL, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 10, no. 6, 1996, pages 1037 - 1043, XP002086054, ISSN: 0960-7412 *
WANG YONGZENG ET AL: "Identification of a novel plant virus promoter using a potyvirus infectious clone.", VIRUS GENES, vol. 20, no. 1, February 2000 (2000-02-01), pages 11 - 17, XP008002062, ISSN: 0920-8569 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517864B2 (en) 2001-05-18 2009-04-14 Sirna Therapeutics, Inc. RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US9592250B2 (en) 2002-02-01 2017-03-14 Life Technologies Corporation Double-stranded oligonucleotides
US7176304B2 (en) 2002-02-20 2007-02-13 Mcswiggen James RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA)
US8846894B2 (en) 2002-02-20 2014-09-30 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US9120858B2 (en) 2011-07-22 2015-09-01 The Research Foundation Of State University Of New York Antibodies to the B12-transcobalamin receptor

Also Published As

Publication number Publication date
AU2001275474A1 (en) 2001-12-24
WO2001096584A2 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
WO2001096584A3 (en) Materials and methods for the control of nematodes
WO2006017538A3 (en) Hk1-binding proteins
WO2001075067A8 (en) Novel nucleic acids and polypeptides
WO2001057188A3 (en) Novel nucleic acids and polypeptides
WO2001057190A3 (en) Novel nucleic acids and polypeptides
WO2002022660A3 (en) Novel nucleic acids and polypeptides
WO2001066689A3 (en) Novel nucleic acids and polypeptides
WO2002031111A3 (en) Novel nucleic acids and polypeptides
WO2002090539A3 (en) Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
WO2001088088A3 (en) Novel nucleic acids and polypeptides
WO2006020768A3 (en) Chemically modified oligonucleotides
WO2005005679A3 (en) Super-hydrophobic surfaces, methods of their construction and uses therefor
AU2001231188A1 (en) Modified low temperature case hardening processes
WO2002070539A3 (en) Novel nucleic acids and polypeptides
WO2007051164A3 (en) Toll like receptor 3 modulators, methods and uses
WO2004080148A3 (en) Novel nucleic acids and polypeptides
WO2003029271A3 (en) Novel nucleic acids and polypeptides
WO2006135793A3 (en) Protein engineering with analogous contact environments
AU3281902A (en) Methods for the production of multimeric proteins, and related compositions
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2002018424A3 (en) Nucleic acids and polypeptides
WO2001079449A3 (en) Novel nucleic acids and polypeptides
WO2005001039A3 (en) Ribozyme-regulated small inhibitory rna (sirna) production and methods of use thereof
AU2001269575A1 (en) Nucleic acid sequences and proteins involved in cellular senescence
MXPA03008005A (en) Method of colouring porous material.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载